Family Site

The contents provided by this page is intended for patients prescribed with Remsima® subcutaneous(SC). If you are an Australian Healthcare Professional , please click the relevant button.

About Remsima® How Remsima® works

About Remsima®

Remsima®(infliximab), is the world’s first biosimilar monoclonal antibody(mAb) for the treatment of autoimmune diseases developed by Celltrion.
Remsima® is developed into dual formulation of intravenous and subcutaneous.1
Remsima® IV was approved by international drug regulatory agencies across about 110 countries including the European Medicines Agency(EMA)1, Therapeutic Goods Administration (TGA) and the U.S. Food and Drug Administration(FDA). In Australia, what is marketed at present is Remsima® SC

Remsima® SC is the world's only SC formulation of infliximab and it has been approved by the European Medicines Agency(EMA) and Therapeutic Goods Administration (TGA). Remsima® SC is available in pre-filled pen and pre-filled syringe with needle guard.1
The Remsima® Infliximab dual formulation provides a tailored treatment based on the individual needs of patients.2

Subcutaneous injection

  • Remsima® 120mg solution for injection in
    pre-filled syringe with needle guard

  • Remsima® 120mg solution for injection in pre-filled pen

  • References

    1. Remsima® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/Remsima®-epar-product-information_en.pdf Accessed 4 Sep 2020.

    2. Jin, Jing-Fen et al. “The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. ” Patient preference and adherence vol. 9 923-42. 2 Jul. 2015, doi:10.2147/PPA.S87271

    Abbreviations

    SC, subcutaneous; AS, ankylosing spondylitis; CD, Crohn's disease; EMA, European Medicines Agency; PsA, psoriatic arthritis; PsO, plaque psoriasis; RA, rheumatoid arthritis; UC, ulcerative colitis